MedTrace Logo

A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis

NCT06931002 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2025-07-09

No results posted yet for this study

Summary

The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are:

* Does viral infection with the common cold lead to an exacerbation in bronchiectasis?
* Does the immune response differ to that of a healthy participant?

Participants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.

Conditions

  • Bronchiectasis Adult
  • Bronchiectasis With Acute Exacerbation
  • Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa
  • Viral Infection
  • Rhinovirus Infection

Interventions

BIOLOGICAL

Rhinovirus A-16 Infection

All participants will be deliberately infected with Rhinovirus A-16

Sponsors & Collaborators

  • Imperial College Healthcare NHS Trust

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Anand Shah, PhD · Imperial College London

  • Aran Singanayagam, PhD · Imperial College London

  • Sebastian Johnston, PhD · Imperial College London

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-24
Primary Completion
2027-04-01
Completion
2027-10-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06931002 on ClinicalTrials.gov